Characteristics of patients in arm A and arm B
| . | Values . | Arm A . | Arm B . | P . |
|---|---|---|---|---|
| No. of patients | 54 | 28 | 26 | |
| Age, y, range (mean) | 37-68 (55) | 45-68 (55.6) | 37-67 (54.3) | .74 |
| Race | ||||
| White, n (%) | 32 (59) | 22 (78) | 10 (38) | .003* |
| African American, n (%) | 21(39) | 5 (18) | 16 (62) | |
| Asian, n (%) | 1 (2) | 1 (4) | 0 | |
| Sex | ||||
| Male, n (%) | 28 (52) | 16 (57) | 12 (46) | .59 |
| Female, n (%) | 26 (48) | 12 (43) | 14 (54) | |
| Myeloma subtypes | ||||
| IgA, n | 15 | 9 | 6 | .08 |
| IgG, n | 35 | 15 | 20 | |
| Light chains, n | 4 | 4 | 0 | |
| Thal maint (patients EFS > 180days) | ||||
| Yes, n | 24 | 7 | 17 | .003* |
| No, n | 22 | 17 | 5 | |
| β-2 microglobulin levels at EN, range (mean) | 0.87-4.13 (1.91) | 0.87-3.33 (1.70) | 0.93-4.13 (2.11) | .03* |
| . | Values . | Arm A . | Arm B . | P . |
|---|---|---|---|---|
| No. of patients | 54 | 28 | 26 | |
| Age, y, range (mean) | 37-68 (55) | 45-68 (55.6) | 37-67 (54.3) | .74 |
| Race | ||||
| White, n (%) | 32 (59) | 22 (78) | 10 (38) | .003* |
| African American, n (%) | 21(39) | 5 (18) | 16 (62) | |
| Asian, n (%) | 1 (2) | 1 (4) | 0 | |
| Sex | ||||
| Male, n (%) | 28 (52) | 16 (57) | 12 (46) | .59 |
| Female, n (%) | 26 (48) | 12 (43) | 14 (54) | |
| Myeloma subtypes | ||||
| IgA, n | 15 | 9 | 6 | .08 |
| IgG, n | 35 | 15 | 20 | |
| Light chains, n | 4 | 4 | 0 | |
| Thal maint (patients EFS > 180days) | ||||
| Yes, n | 24 | 7 | 17 | .003* |
| No, n | 22 | 17 | 5 | |
| β-2 microglobulin levels at EN, range (mean) | 0.87-4.13 (1.91) | 0.87-3.33 (1.70) | 0.93-4.13 (2.11) | .03* |
Thal maint indicates thalidomide maintenance for patients who remained event-free at 180 days after transplantation; and EN, enrollment.
Statistically significant.